Core Points - Plus Therapeutics, Inc. has received an additional 180-day extension from Nasdaq to comply with the $1.00 minimum bid price requirement, now having until May 11, 2026, to meet this requirement [1][2] - The extension does not affect the current listing status of the company's common stock on the Nasdaq Capital Market under the symbol "PSTV" [2] - If the closing bid price reaches at least $1.00 per share for 10 consecutive business days during the extension period, Nasdaq will confirm compliance and close the matter [2] Company Overview - Plus Therapeutics is a clinical-stage pharmaceutical company based in Houston, Texas, focused on developing targeted radiotherapeutics for central nervous system cancers [4] - The company combines image-guided local beta radiation with targeted drug delivery approaches, advancing a pipeline of product candidates, particularly in leptomeningeal metastases and recurrent glioblastoma [4] - Plus Therapeutics has established a supply chain through strategic partnerships to support the development, manufacturing, and potential commercialization of its products [4] Subsidiary Information - CNSide Diagnostics, LLC, a wholly owned subsidiary of Plus Therapeutics, develops proprietary laboratory tests, including CNSide®, to identify tumor cells that have metastasized to the central nervous system [5] - The CNSide® CSF Assay Platform allows for quantitative analysis of cerebrospinal fluid, aiding in the management of patients with leptomeningeal metastases [5]